• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Organigram Holdings Inc.

    3/19/21 4:10:58 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OGI alert in real time by email
    SC 13D 1 d157836dsc13d.htm SC 13D SC 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

     

     

    ORGANIGRAM HOLDINGS INC.

    (Name of Issuer)

    Common Shares, no par value

    (Title of Class of Securities)

    68620P101

    (CUSIP Number)

    John R. Whitener

    BT DE Investments Inc.

    103 Foulk Road, Suite 111

    Wilmington, DE 19803

    (302) 656-1950

    With a copy to:

    Randall A. Hanson, Esq.

    F. Reid Avett, Esq.

    Womble Bond Dickinson (US) LLP

    One West 4th Street

    Winston-Salem, NC 27101

    (336) 721-3600

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    March 10, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      BT DE Investments Inc.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      AF (See Item 3)

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      58,336,392 (See Item 5)

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      58,336,392 (See Item 5)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      58,336,392 (See Item 5)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      19.9% (See Item 5)

    14  

      TYPE OF REPORTING PERSON

     

      CO


      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      British American Tobacco p.l.c.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      AF (See Item 3)

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      England and Wales

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      58,336,392 (See Item 5)

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      58,336,392 (See Item 5)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      58,336,392 (See Item 5)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      19.9% (See Item 5)

    14  

      TYPE OF REPORTING PERSON

     

      CO

    This Statement on Schedule 13D is filed with respect to 58,336,392 common shares, no par value (the “Shares”), of Organigram Holdings Inc. (the “Issuer”), held by BT DE Investments Inc. (the “Purchaser”). The Purchaser is a wholly owned subsidiary of BATUS Holdings Inc., which is a wholly owned subsidiary of Louisville Securities Limited, which is a wholly owned subsidiary of British-American Tobacco (Holdings) Limited, which is a wholly owned subsidiary of B.A.T. Industries p.l.c., which is a wholly owned subsidiary of Weston (2009) Limited, which is a wholly owned subsidiary of British American Tobacco (2009) Limited, which is a wholly owned subsidiary of British American Tobacco (2012) Limited, which is a wholly owned subsidiary of British American Tobacco (1998) Limited, which is a wholly owned subsidiary of British American Tobacco p.l.c. (“BAT”). BAT and the aforementioned wholly owned subsidiaries of BAT are collectively referred to herein as the “BAT Entities”.

    This Statement on Schedule 13D is being filed in connection with the acquisition by the Purchaser of the Shares pursuant to a Subscription Agreement dated as of March 10, 2021, between the Purchaser and the Issuer (the “Subscription Agreement”).


    ITEM 1. SECURITY AND ISSUER

    The class of equity securities to which this statement relates is the Shares of the Issuer. The name of the Issuer is Organigram Holdings Inc. and the principal executive office of the Issuer is located at 35 English Drive, Moncton, New Brunswick Canada E1E 3X3.

    ITEM 2. IDENTITY AND BACKGROUND

    (a) - (c) This statement is being filed jointly by the Purchaser and BAT (together, the “Reporting Persons”). An agreement among the Reporting Persons that this Statement on Schedule 13D be filed on behalf of each of them is attached hereto as Exhibit 99.1.

    The name, state or other place of organization and address of the principal office of each of the Reporting Persons and the other BAT Entities are set forth on Schedule A attached hereto and are incorporated herein by reference. The BAT Entities operate a leading consumer-centric, multi-category consumer goods business dedicated to stimulating the senses of adult consumers worldwide. Alongside the BAT Entities’ traditional cigarette products, the group’s portfolio of non-combustible products includes alternatives such as vapour products, tobacco heating products, and modern oral pouches, as well as traditional oral products such as snus and moist snuff.

    The name, citizenship, business address, present principal occupation or employment, and the name, business address and principal business of any corporation or other organization in which such employment is conducted, of each director and executive officer of the BAT Entities (collectively referred to herein as the “BAT Directors and Officers”) are set forth on Schedule B attached hereto and incorporated herein by reference.

    (d) During the last five years, neither any of the BAT Entities nor, to the knowledge of the Reporting Persons, any of the BAT Directors and Officers, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

    (e) During the last five years, none of the BAT Entities nor, to the knowledge of the Reporting Persons, any of the BAT Directors and Officers, has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

    On March 10, 2021, the Purchaser subscribed for and purchased the Shares at a price of C$3.79 per Share, for an aggregate purchase price of approximately C$221.2 million, pursuant to the Subscription Agreement (the (“Transaction”). The source of funds for such purchase was dividends from other U.S. subsidiaries of BAT.

    ITEM 4. PURPOSE OF TRANSACTION

    The Purchaser entered into the Transaction as part of a strategic investment in the Issuer. The Purchaser intends to review its investment in the Issuer on a continuing basis and may, subject to the terms of the Investor Rights Agreement (as defined below), depending upon a number of factors including market and other conditions, increase or decrease its beneficial ownership, degree of control or influence, direction or economic exposure over securities of the Issuer through market transactions, private agreements, treasury issuances, exercise of options, convertible securities, derivatives, swaps or otherwise.

    Pursuant to the Investor Rights Agreement, dated March 10, 2021, between the Purchaser and the Issuer entered into in connection with the Transaction (the “Investor Rights Agreement”), the Purchaser has the right to nominate up to 20% of the board of directors of the Issuer (the “Board”), subject to the Purchaser maintaining certain share ownership thresholds. One nominee of the Purchaser, Mr. Jeyan Heper, was appointed on March 10, 2021 and a second nominee is expected to be appointed to the Board in due course. The Purchaser may, subject to the terms and conditions of its nomination rights, replace its nominee directors from time to time. In addition, the Purchaser will be provided with certain governance rights, so long as it maintains certain share ownership thresholds, including pre-emptive rights, top-up rights and customary piggyback registration rights. The Purchaser may engage with the Board regarding the Issuer’s business and prospects.


    The Purchaser and the Issuer are parties to a Collaboration Agreement, pursuant to which the Purchaser and the Issuer and their affiliates have agreed to jointly develop products, intellectual property or technologies the parties mutually agree to develop. See Item 6 of this Statement on Schedule 13D for more information on the Collaboration Agreement.

    ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

     

      (a)

    See items 7 through 13 on the cover pages to this Statement on Schedule 13D. The Purchaser is a wholly owned subsidiary of BATUS Holdings Inc., which is a wholly owned subsidiary of Louisville Securities Limited, which is a wholly owned subsidiary of British-American Tobacco (Holdings) Limited, which is a wholly owned subsidiary of B.A.T. Industries p.l.c., which is a wholly owned subsidiary of Weston (2009) Limited, which is a wholly owned subsidiary of British American Tobacco (2009) Limited, which is a wholly owned subsidiary of British American Tobacco (2012) Limited, which is a wholly owned subsidiary of British American Tobacco (1998) Limited, which is a wholly owned subsidiary of BAT. In addition to the Purchaser, each of BATUS Holdings Inc., Louisville Securities Limited, British-American Tobacco (Holdings) Limited, B.A.T. Industries p.l.c., Weston (2009) Limited, British American Tobacco (2009) Limited, British American Tobacco (2012) Limited, British American Tobacco (1998) Limited and BAT may be considered to be a beneficial owner of the Shares by virtue of their direct and indirect ownership of all of the equity and voting power of the Purchaser. The Shares comprise approximately 19.9% of the outstanding Shares (based on 293,147,699 Shares outstanding as of March 10, 2021, following the completion of the Transaction).

     

      (b)

    See items 7 through 13 on the cover pages to this Statement on Schedule 13D. The Purchaser has power both to dispose of and exercise the voting rights attributable to the Shares. Each of BATUS Holdings Inc., Louisville Securities Limited, British-American Tobacco (Holdings) Limited, B.A.T. Industries p.l.c., Weston (2009) Limited, British American Tobacco (2009) Limited, British American Tobacco (2012) Limited, British American Tobacco (1998) Limited and BAT may be deemed to control the Purchaser and therefore share voting power and investment power with respect to the Shares. See Item 2 of this Statement on Schedule 13D for information on the BAT Entities.

     

      (c)

    Except for the subscription and purchase by the Purchaser from the Issuer of the Shares on March 10, 2021, at a price per share of C$3.79 pursuant to the Subscription Agreement as set out above, none of the Reporting Persons has effected any transaction in Shares during the last 60 days.

     

      (d)

    No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares beneficially owned by the Reporting Persons.

     

      (e)

    Not applicable.

    ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

    The Issuer and the Purchaser are parties to the Investor Rights Agreement. Pursuant to, and on the terms and conditions of, the Investor Rights Agreement:

     

      •  

    the Purchaser, BAT and their affiliates (the “BAT Group Permitted Holders”) have the right to nominate up to 20% of the Board, rounding up to the nearest whole member for so long as the BAT Group Permitted Holders maintain at least 15% of the Issuer, and up to 10% of the Board, for so long as the BAT Group Permitted Holders maintain at least 10% of the Issuer (but less than 15%);

     

      •  

    for so long as the BAT Group Permitted Holders have the right to nominate at least one member of the Board, the BAT Group Permitted Holders have the right to designate one voting member to the Investment Committee of the Board and one non-voting observer to any other committee of the Board to the extent that a nominee of the BAT Group Permitted Holders is not already a voting member of such Committee;


      •  

    the BAT Group Permitted Holders have pre-emptive rights to subscribe for securities in issuances by the Issuer, or to make certain top-up purchases following a distribution in which it did not participate, in each case on the same terms and conditions as all other participants in the issuance up to an amount so as to prevent dilution of the BAT Group Permitted Holders’ ownership percentage in the Issuer;

     

      •  

    the BAT Group Permitted Holders have customary piggyback registration rights to sell all or a portion of the securities of the Issuer held by the BAT Group Permitted Holders in any distribution of shares in the capital of the Issuer to the public by way of a prospectus in Canada or a registration statement in the United States, except for any at-the-market distribution;

     

      •  

    the Purchaser and its affiliates have agreed not to purchase any voting or equity securities of the Issuer or any of its subsidiaries that would result in ownership of more than 19.9% of the voting or equity securities of the Issuer or any of its subsidiaries, enter into or pursue any acquisition or other business combination involving the Issuer or any of its subsidiaries, solicit proxies or otherwise attempt to influence the conduct of the shareholders of the Issuer, or make any public announcement or other actions with respect to any of the foregoing, in each case, for two years following the execution of the Investor Rights Agreement, subject to certain exceptions; and

     

      •  

    the Purchaser has agreed to a lock-up from transferring the Shares for one year following the execution of the Investor Rights Agreement, subject to certain exceptions.

    The Investor Rights Agreement will terminate upon the earliest of the BAT Group Permitted Holders ceasing to hold any shares in the capital of the Company, by the mutual consent of the Issuer and the Purchaser or the dissolution or liquidation of the Issuer.

    The Issuer and the Purchaser are parties to the Subscription Agreement, pursuant to which the Purchaser subscribed for and purchased the Shares at a price of C$3.79 per Share, for an aggregate purchase price of approximately C$221.2 million.

    The foregoing descriptions are summaries of the material terms of the Investor Rights Agreement and Subscription Agreement and are qualified in in their entirety by the full terms and conditions of the Investor Rights Agreement and Subscription Agreement, which are incorporated herein by reference.

    The Purchaser and the Issuer are parties to a Collaboration Agreement, pursuant to which the Purchaser and the Issuer and their affiliates have agreed to jointly develop products, intellectual property or technologies the parties mutually agree to develop. The Issuer has agreed to reserve approximately C$30 million from the proceeds of the Transaction to fulfill its obligations under the Collaboration Agreement. The Purchaser and its affiliates will own all intellectual property developed under this collaboration and will grant to the Issuer a perpetual, global license to all such intellectual property. Each party has also agreed to grant to the other a non-exclusive, perpetual and irrevocable license to certain existing intellectual property of such party and its affiliates for purposes of conducting the development activities and exploiting the products, technologies and intellectual property created by the collaboration, subject to certain restrictions. The Reporting Persons expect that affiliates of BAT and the Issuer may negotiate additional arms-length commercial arrangements in the future.


    ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

     

    Exhibit 99.1    Joint Filing Agreement dated as of March 19, 2021, between the Reporting Persons (filed herewith).
    Exhibit 99.2    Investor Rights Agreement, dated as of March 10, 2021, between the Purchaser and the Issuer (filed herewith). *
    Exhibit 99.3    Subscription Agreement, dated as of March 10, 2021, between the Purchaser and the Issuer (filed herewith). *

     

    *

    Confidential treatment requested.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: March 19, 2021

     

    BT DE Investments Inc.
    By:  

    /s/ John R. Whitener

      Name: John R. Whitener
      Title: Treasurer
    British American Tobacco p.l.c.
    By:  

    /s/ Tadeu Marroco

      Name: Tadeu Marroco
      Title: Finance and Transformation Director


    SCHEDULE A

    BAT ENTITIES

     

    BAT Entity   

    Name, state or other place of

    organization

       Address of the principal office
    British American Tobacco p.l.c.    England and Wales    Globe House, 4 Temple Place, London WC2R 2PG, United Kingdom
    British American Tobacco (1998) Limited    England and Wales    Globe House, 4 Temple Place, London WC2R 2PG, United Kingdom
    British American Tobacco (2012) Limited    England and Wales    Globe House, 4 Temple Place, London WC2R 2PG, United Kingdom
    British American Tobacco (2009) Limited    England and Wales    Globe House, 4 Temple Place, London WC2R 2PG, United Kingdom
    Weston (2009) Limited    England and Wales    Globe House, 4 Temple Place, London WC2R 2PG, United Kingdom
    B.A.T. Industries p.l.c.    England and Wales    Globe House, 4 Temple Place, London WC2R 2PG, United Kingdom
    British-American Tobacco (Holdings) Limited    England and Wales    Globe House, 4 Temple Place, London WC2R 2PG, United Kingdom
    Louisville Securities Limited    England and Wales    Globe House, 4 Temple Place, London WC2R 2PG, United Kingdom
    BATUS Holdings Inc.    Delaware   

    103 Foulk Road, Suite 201-3,

    Wilmington, DE 19803

    BT DE Investments Inc.    Delaware   

    103 Foulk Road, Suite 111,

    Wilmington, DE 19803


    SCHEDULE B

    BAT DIRECTORS AND OFFICERS

    The name, country of citizenship and current principal occupation or employment of each of the BAT Directors and Officers are set forth below. Unless otherwise indicated in the tables below (i) each occupation set forth opposite an individual’s name refers to a position with a BAT Entity and (ii) the business address of such individual is Globe House, 4 Temple Place, London WC2R 2PG, United Kingdom.

    British American Tobacco p.l.c.

    Name (and business address where not Globe House, 4 Temple
    Place, London WC2R 2PG, United Kingdom)

      

    Country of Citizenship

      

    Current Principal Occupation or Employment (and business
    address and principal business of any corporation or other
    organization other than a BAT Entity)

    Richard Burrows (Chairman)    Republic of Ireland    Chairman of BAT and Supervisory Board member of Carlsberg A/S
    Luc Jobin (Chairman Designate)    Canada    Chairman Designate of BAT, Independent Director of Hydro-Québec and Gildan Activewear Inc.
    Dimitri Panayotopoulos (Senior Independent Director)    Greece and United Kingdom    Senior Independent Director of BAT, Senior Advisor at the Boston Consulting Group, Advisory Board member of JBS USA and a Board member of IRI and North Atlantic Acquisition Corporation
    Jack Bowles (Chief Executive)    France    Chief Executive of BAT
    Tadeu Marroco (Finance and Transformation Director)    Brazil    Finance and Transformation Director of BAT
    Susan Farr (Non-Executive Director)    United Kingdom    Non-Executive Director of BAT, Accsys Technologies plc, Helical plc and Unlimited Group Ltd
    Jerry Fowden (Non-Executive Director)    United Kingdom    Chairman of Primo Water Corporation and Non-Executive Director of BAT and Constellation Brands, Inc.
    Karen Guerra (Non-Executive Director)    United Kingdom    Non-Executive Director of BAT and Amcor p.l.c
    Dr. Marion Helmes (Non-Executive Director)    Germany    Chairwoman of the Supervisory Board of ProSiebenSat.1 Media, Supervisory Board member of Siemens Healthineers AG and Heineken N.V. and Non-Executive Director of BAT
    Holly Keller Koeppel (Non-Executive Director)    U.S.A.    Non-Executive Director of BAT and Vesuvius plc and a Director of The AES Corporation and Arch Coal Inc.
    Savio Kwan (Non-Executive Director)    United Kingdom    Co-Founder and CEO of A&K Consulting Co Ltd, Non-Executive Director of BAT, The Alibaba Hong Kong Entrepreneur Fund, Crossborder Innovative Ventures International Limited and Advisory Board member of Homaer Financial.
    Darrell Thomas (Non-Executive Director)    U.S.A.    Vice President and Treasurer of Harley-Davidson, Inc., Non-Executive Director of BAT and Board member of Sojourner Family Peace Center Inc.


    British American Tobacco (1998) Limited

    Name (and business address where not Globe House, 4 Temple
    Place, London WC2R 2PG, United Kingdom)

      

    Country of Citizenship

      

    Current Principal Occupation or Employment (and business
    address and principal business of any corporation or other
    organization other than a BAT Entity)

    Jerome Abelman    U.S.A.    Director, Legal and External Affairs and General Counsel
    Hae In Kim    South Korea    Director, Talent, Culture and Inclusion
    Tadeu Marroco    Brazil    Finance and Transformation Director
    Kingsley Wheaton    United Kingdom    Chief Marketing Officer

    British American Tobacco (2012) Limited

    Name (and business address where not Globe House, 4 Temple
    Place, London WC2R 2PG, United Kingdom)

      

    Country of Citizenship

      

    Current Principal Occupation or Employment (and business
    address and principal business of any corporation or other
    organization other than a BAT Entity)

    David Booth    United Kingdom    Group Chief Accountant
    Anthony Cohn    United Kingdom    Head of Corporate Tax - UK
    Ruth Wilson    United Kingdom    Head of Group Corporate Governance
    Ridirectors Limited (Globe House, 1 Water Street, London, England, WC2R 3LA)    Incorporated in the United Kingdom    Corporate director (non-trading company)

    British American Tobacco (2009) Limited

    Name (and business address where not Globe House, 4 Temple
    Place, London WC2R 2PG, United Kingdom)

      

    Country of Citizenship

      

    Current Principal Occupation or Employment (and business
    address and principal business of any corporation or other
    organization other than a BAT Entity)

    David Booth    United Kingdom    Group Chief Accountant
    Anthony Cohn    United Kingdom    Head of Corporate Tax - UK
    Ruth Wilson    United Kingdom    Head of Group Corporate Governance
    Oliver Wolfensberger    Swiss    Head of Corporate Treasury
    Ridirectors Limited (Globe House, 1 Water Street, London, England, WC2R 3LA)    Incorporated in the United Kingdom    Corporate director (non-trading company)

    Weston (2009) Limited

    Name (and business address where not Globe House, 4 Temple
    Place, London WC2R 2PG, United Kingdom)

      

    Country of Citizenship

      

    Current Principal Occupation or Employment (and business
    address and principal business of any corporation or other
    organization other than a BAT Entity)

    Jerome Abelman    U.S.A    Director, Legal and External Affairs and General Counsel
    Tadeu Marroco    Brazil    Finance and Transformation Director


    B.A.T. Industries p.l.c.

    Name (and business address where not Globe House, 4 Temple
    Place, London WC2R 2PG, United Kingdom)

      

    Country of Citizenship

      

    Current Principal Occupation or Employment (and business
    address and principal business of any corporation or other
    organization other than a BAT Entity)

    Andrew James Barrett    United Kingdom    Group Financial Controller and Head of M&A
    Steven Dale    United Kingdom    Group Head of Corporate Tax

    British-American Tobacco (Holdings) Limited

    Name (and business address where not Globe House, 4 Temple
    Place, London WC2R 2PG, United Kingdom)

      

    Country of Citizenship

      

    Current Principal Occupation or Employment (and business
    address and principal business of any corporation or other
    organization other than a BAT Entity)

    Jerome Abelman    U.SA    Director, Legal and External Affairs and General Counsel
    Marina Bellini    Italy, Brazil    Director, Digital and Information
    Jack Bowles    France    Chief Executive
    Luciano Comin    Italy, Argentina    Regional Director, Americas and Sub-Saharan Africa
    Mihovil James Dijanosic    Australia    Regional Director, Asia-Pacific and Middle East
    Zafar Khan    Pakistan    Director, Operations
    Hae In Kim    South Korea    Director, Talent, Culture and Inclusion
    Paul Lageweg    Netherlands    Director, New Categories
    Tadeu Marroco    Brazil    Finance and Transformation Director
    Guy Meldrum    New Zealand    President and CEO, Reynolds American Inc.
    David O’Reilly    United Kingdom    Director, Scientific Research
    Johan Vandermeulen    Belgium    Regional Director, Europe and North Africa
    Kingsley Wheaton    United Kingdom    Chief Marketing Officer

    Louisville Securities Limited

    Name (and business address where not Globe House, 4 Temple
    Place, London WC2R 2PG, United Kingdom)

      

    Country of Citizenship

      

    Current Principal Occupation or Employment (and business
    address and principal business of any corporation or other
    organization other than a BAT Entity)

    Andrew James Barrett    United Kingdom    Group Financial Controller and Head of M&A
    Steve Dale    United Kingdom    Group Head of Corporate Tax
    Neil Wadey    United Kingdom    Group Treasurer
    Ruth Wilson    United Kingdom    Head of Group Corporate Governance
    Ridirectors Limited (Globe House, 1 Water Street, London, England, WC2R 3LA)    Incorporated in the United Kingdom    Corporate director (non-trading company)


    BATUS Holdings Inc.

    Name (and business address where not Globe House, 4 Temple
    Place, London WC2R 2PG, United Kingdom)

      

    Country of Citizenship

      

    Current Principal Occupation or Employment (and business
    address and principal business of any corporation or other
    organization other than a BAT Entity)

    Alden H. Smith (Vice President and Director)

    401 North Main Street, Winston-Salem, NC 27101

       U.S.A.    Managing Counsel – Corporate of RAI Services Company, whose principal business address is 401 North Main Street, Winston-Salem, NC 27101

    Lisa M. Oakes (Secretary and Director)

    4250 Lancaster Pike, Suite 302, Wilmington, DE 19805

       U.S.A.    Vice President of Corporation Service Company, whose business address is 4250 Lancaster Pike, Suite 302, Wilmington, DE 19805, and whose principal business is the provision of corporate and administrative services.

    Timothy J. Hazlett (President and Director)

    627 Eagle Watch Lane, Osprey, FL 34229

       U.S.A.    Managing Member of T. J. Hazlett, LLC, whose business address is 627 Eagle Watch Lane, Osprey, FL 34229, and whose principal business is the provision of consulting services.

    John R. Whitener (Director)

    401 North Main Street, Winston-Salem, NC 27101

       U.S.A.    Senior Vice President Controller – Finance & Accounting and Treasurer of RAI Services Company, whose principal business address is 401 North Main Street, Winston-Salem, NC 27101

    Nancy G. Sturgeon (Vice President Tax)

    401 North Main Street, Winston-Salem, NC 27101

       U.S.A.    Senior Vice President – Tax and Assistant General Counsel of RAI Services Company, whose principal business address is 401 North Main Street, Winston-Salem, NC 27101

    Caroline M. Price (Treasurer)

    301 North Market Street, Suite 1402

    Wilmington, Delaware 19801

       U.S.A.    President and Senior Manager Investments of Reynolds Finance Company, whose principal business address is 301 North Market Street, Suite 1402, Wilmington, Delaware 19801

    Patrick Z. Messick (Assistant Secretary)

    401 North Main Street, Winston-Salem, NC 27101

       U.S.A.    Senior Director Income Tax of RAI Services Company, whose principal business address is 401 North Main Street, Winston-Salem, NC 27101


    BT DE Investments Inc.

    Name (and business address where not Globe House, 4 Temple
    Place, London WC2R 2PG, United Kingdom)

      

    Country of Citizenship

      

    Current Principal Occupation or Employment (and business
    address and principal business of any corporation or other
    organization other than a BAT Entity)

    James J. Murphy (President and Director)

    401 North Main Street, Winston-Salem, NC 27101

       United Kingdom and Republic of Ireland    Executive Vice President R&D and Scientific and Regulatory Affairs of RAI Services Company, whose principal business address is 401 North Main Street, Winston-Salem, NC 27101

    John R. Whitener (Treasurer and Director)

    401 North Main Street, Winston-Salem, NC 27101

       U.S.A.    Senior Vice President Controller – Finance & Accounting and Treasurer of RAI Services Company, whose principal business address is 401 North Main Street, Winston-Salem, NC 27101

    Matthew R. Triplett (Secretary)

    401 North Main Street, Winston-Salem, NC 27101

       U.S.A.    Senior Counsel – Commercial/Corporate of RAI Services Company, whose principal business address is 401 North Main Street, Winston-Salem, NC 27101

    Patrick Z. Messick (Assistant Secretary)

    401 North Main Street, Winston-Salem, NC 27101

       U.S.A.    Senior Director Income Tax of RAI Services Company, whose principal business address is 401 North Main Street, Winston-Salem, NC 27101

     

    Get the next $OGI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OGI

    DatePrice TargetRatingAnalyst
    7/17/2024Speculative Buy
    Canaccord Genuity
    4/15/2024Neutral → Buy
    Alliance Global Partners
    1/13/2023Hold → Buy
    Stifel
    1/12/2022Hold → Speculative Buy
    Canaccord Genuity
    1/12/2022$5.70 → $5.30Overweight
    Cantor Fitzgerald
    12/8/2021$5.50 → $5.70Overweight
    Cantor Fitzgerald
    More analyst ratings

    $OGI
    Leadership Updates

    Live Leadership Updates

    See more
    • Organigram Announces Results of Annual and Special Meeting, including Shareholder Approval of Name Change to Organigram Global Inc.

      Organigram Holdings Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI) announced today the results of voting at its annual general and special meeting of shareholders (the "Shareholders") held virtually on March 24, 2025 (the "Meeting"). Shareholder Approval of the Name Change and Articles of Amendment At the Meeting, a special resolution approving an amendment to the articles of the Company to change the name of the Company to "Organigram Global Inc." (the "Name Change"), was approved by the affirmative vote of 95.778% of the votes represented at the Meeting. The Name Change remains subject to regulatory approvals, including the approval of the TSX. The TSX has conditionally ap

      3/24/25 8:30:00 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Announces Appointment of Craig Harris to Board of Directors

      Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced the appointment of Craig Harris to the Organigram Board of Directors effective today. Craig brings over 20 years of experience as a commercial lawyer, with a background in private practice and legal and regulatory engagement roles for various corporations. He is currently the Assistant General Counsel – Corporate & Commercial Legal at British American Tobacco plc (BAT). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240729497569/en/Craig Harris (Photo: Business Wire) "We are thrilled to welcome Cra

      7/29/24 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Announces Appointment of Karina Gehring to Board of Directors

      Organigram Holdings Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI), announced the appointment of Karina Gehring to the Organigram Board of Directors at the Company's annual general and special meeting held on January 18, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240119151071/en/Karina Gehring (Photo: Business Wire) "We are thrilled to welcome Karina to our Board of Directors. Her extensive expertise in marketing and brand management combined with her ongoing experience with BAT will be a tremendous asset to our Board," said Peter Amirault, Board Chair, Organigram. Karina is one of two directors (includi

      1/19/24 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Organigram Reports Record Second Quarter Fiscal 2025 Results

      Record gross revenue of $102.8 million and record net revenue of $65.6 million Adjusted EBITDA1 of $4.9 million Net income of $42.5 million Increase in anticipated Motif cost synergies to $15 million from $10 million Total cash position of $83.4 million2 and negligible debt Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced its record results for the second quarter ended March 31, 2025 ("Q2 Fiscal 2025"). The Q2 Fiscal 2025 results include a full quarter of consolidated financials from the Company's acquisition of Motif Labs Ltd. ("Motif") on December 6, 2024. Q2 FISCAL 2025 HIGHLIGHTS Gross r

      5/12/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Global's Collective Project Wins Big at the 2025 High Spirits Awards in California

      Wins gold medal for Blood Orange, Yuzu & Vanilla and platinum medal for Mango, Pineapple & Coconut Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, is pleased to announce that its recently acquired business, Collective Project, has won recognition at the 2025 High Spirits Awards only a few short months following the launch of the brand in the U.S. The brand received a gold award for Blood Orange, Yuzu & Vanilla and a platinum award for Mango, Pineapple & Coconut hemp-derived THC beverages. High Spirits Awards is a competition launched by L.A. Spirits Awards in 2023 to identify and reward excellence among the growi

      5/7/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Global Wins "Exporter of the Year" at the 2025 New Brunswick Export Awards

      Award recognizes exceptional export growth, product innovation, and global market leadership Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), ("the Company" or "Organigram"), Canada's #1 cannabis company by market share, is pleased to announce it has been named Exporter of the Year by Opportunities New Brunswick ("ONB") as part of the 2025 New Brunswick Export Awards, ONB's flagship annual event recognizing the successes and innovative approaches of New Brunswick's many exporting companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250505021217/en/ This honour recognizes Organigram's significant growth in international cannab

      5/5/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Organigram Holdings Inc.

      SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

      12/10/24 7:10:15 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Organigram Holdings Inc.

      SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

      9/3/24 9:30:26 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Organigram Holdings Inc. (Amendment)

      SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

      1/25/24 5:23:26 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity resumed coverage on OrganiGram

      Canaccord Genuity resumed coverage of OrganiGram with a rating of Speculative Buy

      7/17/24 12:18:49 PM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OrganiGram upgraded by Alliance Global Partners

      Alliance Global Partners upgraded OrganiGram from Neutral to Buy

      4/15/24 8:40:01 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OrganiGram upgraded by Stifel

      Stifel upgraded OrganiGram from Hold to Buy

      1/13/23 7:36:46 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGI
    SEC Filings

    See more
    • SEC Form 6-K filed by Organigram Global Inc.

      6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

      5/12/25 7:39:04 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Organigram Global Inc.

      6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

      5/7/25 9:38:26 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Organigram Global Inc.

      6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

      5/5/25 11:48:28 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGI
    Financials

    Live finance-specific insights

    See more
    • Organigram Reports Record Second Quarter Fiscal 2025 Results

      Record gross revenue of $102.8 million and record net revenue of $65.6 million Adjusted EBITDA1 of $4.9 million Net income of $42.5 million Increase in anticipated Motif cost synergies to $15 million from $10 million Total cash position of $83.4 million2 and negligible debt Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced its record results for the second quarter ended March 31, 2025 ("Q2 Fiscal 2025"). The Q2 Fiscal 2025 results include a full quarter of consolidated financials from the Company's acquisition of Motif Labs Ltd. ("Motif") on December 6, 2024. Q2 FISCAL 2025 HIGHLIGHTS Gross r

      5/12/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram to Report Second Quarter Fiscal 2025 Results on May 12, 2025

        Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced today it will report earnings results for its second quarter fiscal 2025 ended March 31, 2025, on Monday, May 12, 2025, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Monday, May 12, 2025 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I96766371 To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After registering, a co

      5/2/25 6:00:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organigram Enters U.S. Through Acquisition of Collective Project Beverages

      Acquisition Marks Commercial Market Entry in the Fast-Growing Hemp-Derived THC Beverage Category in the U.S. and the Emerging Canadian Cannabis Beverage Category Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, is pleased to announce the acquisition of 100% of the issued and outstanding shares of Collective Project Limited ("CPL") for upfront consideration of approximately C$6.2 million, potential milestone payments and potential earnout payments totaling in the aggregate up to C$24M for the twelve-month periods ending September 30, 2025 and September 30, 2026. This press release features multimedia. View the full

      4/1/25 7:47:00 AM ET
      $OGI
      Biotechnology: Pharmaceutical Preparations
      Health Care